Clinical Heterogeneity in ME/CFS. A Way to Understand Long-COVID19 Fatigue.
Murga, Iñigo, Aranburu, Larraitz, Gargiulo, Pascual A et al. · Frontiers in psychiatry · 2021 · DOI
Quick Summary
This study examined 84 ME/CFS patients and 22 healthy controls using questionnaires to measure fatigue, pain, sleep quality, heart rate problems, thinking difficulties, mood, and other symptoms. Researchers used statistical clustering to group patients into five distinct subtypes based on their symptom patterns. The findings suggest that ME/CFS is not one-size-fits-all—some patients have high anxiety and depression without fibromyalgia, while others have fibromyalgia combined with heart rate regulation problems, hormone imbalances, or immune issues.
Why It Matters
ME/CFS is clinically heterogeneous, and identifying objective phenotypes may enable personalized treatment approaches and help clarify why patients respond differently to interventions. This phenotyping approach also provides a framework for understanding Long-COVID fatigue, potentially benefiting the growing population of post-infection patients. Demonstrating measurable, distinct symptom profiles validates the biological complexity of ME/CFS and supports the need for subtype-specific research.
Observed Findings
Five distinct patient phenotypes identified: two non-fibromyalgia groups (13 and 20 patients) differentiated by anxiety-depression levels, and three fibromyalgia-predominant groups stratified by dysautonomia (17 patients), neuroendocrine dysfunction (15 patients), or immune abnormalities (19 patients).
Women scored significantly higher than men on cognitive assessments, pain scales, and depression measures.
Fibromyalgia was present in three of five phenotype clusters, suggesting it commonly co-occurs with specific dysregulatory features rather than appearing uniformly across ME/CFS.
No gender-specific phenotype was identified; men and women distributed across all five clusters.
Inferred Conclusions
ME/CFS comprises multiple biologically and clinically distinct subtypes rather than a single homogeneous condition.
Clustering analysis can objectively characterize and differentiate elusive ME/CFS symptom profiles, supporting precision medicine approaches.
Fibromyalgia in ME/CFS appears linked to dysautonomic, neuroendocrine, or immune dysregulation in distinct subgroups.
Gender influences symptom expression and severity but does not define separate disease phenotypes.
Remaining Questions
Are these five phenotypes stable over time, or do patients transition between clusters as disease progresses?
What This Study Does Not Prove
This study does not establish causation—it identifies associations between symptoms, not mechanisms. The cross-sectional design captures patients at one time point, so it cannot determine whether phenotypes are stable over time or if they represent disease stages. The relatively small cohort (n=84) limits generalizability, and the findings require replication in larger, diverse populations before clinical application.